Tolerance-induction protocol in HIV-infected patients with drug hypersensitivity;Place de l'induction de tolérance chez le sujet VIH intolérant aux médicaments

Revue Francaise d'Allergologie et d'Immunologie Clinique

Volumn 42, Issue 8, 2002, Pages 757-762

  Messaad, D ^a   Reynes, J ^a   Faucherre, V ^a   Bousquet, J ^a   Demoly, P ^a  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Cotrimoxazole; Drug hypersensitivity; Efavirenz; HIV; Nelfinavir; Nevirapine; Tolerance induction

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; NELFINAVIR; NEVIRAPINE;

ADULT; ARTICLE; ASTHENIA; CLINICAL FEATURE; DOSE RESPONSE; DRUG ANALYSIS; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PAPULAR SKIN DISEASE; RASH; SYMPTOM; URTICARIA;

EID: 17144456104     PISSN: 03357457     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0335-7457(02)00224-1     Document Type: Article

References (27)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 1998;279:1200-5.
2. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993;328:1670-4.
3. Bocquet H, Chosidow O. Les toxidermies au cours du Sida. Rev Fr Allergol 1997;37:678-84.
4. Ioannidis JPA, Cappeleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996;156:177-88.
5. Demoly P, Messaad D, Sahla H, Godard PH, Michel FB, Bousquet J. Désensibilisation et accoutumance médicamenteuse chez le sujet VIH. Rev Fr Allergol Immunol Clin 1998;4:385-9.
6. Demoly P, Messaad D, Sahla H, Fabre J, Faucherre V, André P, et al. Six hour trimethoprim-sulfamethoxazole-graded challenge in HIV-infected patient. J Allergy Clin Immunol 1998;102:1033-6.
7. Demoly P, Messaad D, Fabre J, Reynes J, Bousquet J. Nevirapine-induced cutaneous hypersensitivity reactions and successful tolerance induction. J Allergy Clin Immunol 1999;104:504-5.
8. Demoly P, Messaad D, Trylesinsky A, Faucherre V, Fabre J, Reynes J, et al. Nelfinavir induced urticaria and successful desensitization. J Allergy Clin Immunol 1998;102:875-6.
9. Demoly P, Messaad D, Reynes J, Faucherre V, Bousquet J. Trimethoprim-sulfamethoxazole-graded challenge in HIV-infected patients: Long-term follow-up regarding efficacy and safety. J Allergy Clin Immunol 2000;105:588-9.
10. Rich JD, Sullivan T, Greineder D, Kazanjian PH. Trimethoprim/sulfamethoxazole incremental dose regimen in human immunodeficiency virus-infected persons. Ann Allergy Asthma Immunol 1997;79:409-14.
11. Carr A, Penny R, Cooper DA. Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients. AIDS 1993;7:65-71.
12. Absar N, Daneshvar H, Beall G. Desensitization to trimethoprim/sulfamethoxazole in HIV-infected patients. J Allergy Clin Immunol 1994;93:1001-5.
13. Bachmeyer C, Salmon D, Guérin C, Barré C, Hazebroucq G, Sicard D, et al. Trimethoprim-sulphamethoxazole desensitization in HIV-infected patients: An open study. AIDS 1995;9:299-312.
14. Bissuel F, Cotte L, Crapanne J-B, Rougier P, Schlienger I, Trepo C. Trimethoprim-sulphamethoxazole rechallenge in 20 previously allergic HIV-infected patients after homeopathic desensitization. AIDS 1995;9:407-8.
15. Gluckstein D, Ruskin J. Rapid oral desensitization to trimethoprimsulfamethoxazole (TMP-SMZ): Use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis 1995;20:849-53.
16. Nguyen MT, Weiss PJ, Wallace MR. Two-day oral desensitization to trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS 1995;9:573-5.
17. Caumes E, Guermonprez G, Katlama C, Bricaire F. A life-threatening adverse reaction during trimethoprim-sulfamethoxazole desensitization in a previous hypersensitive patient infected with human immunodeficiency virus. Clin Infect Dis 1996;23:131-4.
18. Para MF, Finkelstein D, Becker S, Dohn M, Walawander A, Black A. Reduced toxicity with gradual initiation of trimethoprimsulfamethoxazole as primary prophylaxies for Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr 2000;24:337-43.
19. Bonfanti P. Pusterla L, Parazzini F, Libanore M, Cagni AE, Franzetti M, et al. The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensibilité to TMP-SMX: A randomized multicentric study. Biomed Pharmacother 2000;54:45-9.
20. Carr A, Penny R, Cooper DA. Allergy and desensitization to zidovudine in patients with acquired immunodeficiency syndrome (AIDS). J Allergy Clin Immunol 1993;91:683-5.
21. Duque S, de la Puente J, Rodriguez F, Pellon FF, Maquiera E, Jerez J. Zidovudine-related erythroderma and successful desensitization. J Allergy Clin Immunol 1996;98:234-5.
22. Lauter CB, Haver T, Davidson A. Pruritus and urticaria due to lamivudine (3TC, Epivir®): Allergic evaluation of a patient on combination therapy and successful oral "rush" desensitization. J Allergy Clin Immunol 1997;99:A1757.
23. Abraham PE, Sorensen SJ, Baker WH, Cushing HE. Nelfinavir desensitization. Ann Pharmacother 2001;35:553-5.
24. Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double blind trial comparing combination of nevirapine, didanosine and zidovudine for HIV infected patients: The INCAS trial. JAMA 1998;279:930-7.
25. Barmer A, Myers M. Nevirapine and rashes. Lancet 1998;351:1133.
26. Barreiro P, Soriano V, Casas E, Estrada V, Tellez MJ, Hoetelmans R, et al. Prevention of nevirapine-associated exanthema using slow dose escalator and/or corticosteroids. AIDS 2000;14:2153-7.
27. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-infection in adults. N Engl J Med 1999;341:1865-73.